November 2, 2026 · Phase 2 readout
ENLV Phase 2 readout: a negative outcome, -20.8%
On November 2, 2026, Allocetra — Enlivex Therapeutics Ltd. (Osteoarthritis, Knee) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -20.8% in the window around the event. It had already run +356.4% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$1.78
1d before
$1.41
Event day
$1.46
1d after
$1.24
5d after
Our prediction vs. the result
CatalystAlert called this one up (+2.6% expected); the stock actually moved -20.8%. Model confidence at the time: 40%.
See the full scored track recordPre-catalyst setup
+356.4%
30-day run-up
500498%
30-day volatility
0.1×
volume spike